Exonate appoints Olav Hellebø as Chief Executive Officer

CAMBRIDGE, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the appointment of Olav Hellebø as Chief Executive Officer. Olav will lead the company as it strengthens its executive team and advances toward key clinical and corporate milestones, including initiating a Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease.Olav brings extensive b